# A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants

> **NCT07730554** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 84 (actual)

## Conditions studied

- Forehead Lines

## Interventions

- **DRUG:** AGN-151586

## Key facts

- **NCT ID:** NCT07730554
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-07-22
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730554, "A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*